StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

BioXcel Therapeutics's enterprise value was $92.39M on Oct 19, 2026, against $104.82M a year earlier. Over the last 5 years it ranged from $43.35M to $797.78M, with a median of $111.10M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Oct 19, 2026$92.39M-12.0%
2025Dec 31, 2025$104.94M+31.3%
2024Dec 31, 2024$79.93M-16.3%
2023Dec 29, 2023$95.49M-79.3%
2022Dec 30, 2022$461.32M+46.0%
2021Dec 31, 2021$315.92M-64.6%
2020Dec 31, 2020$891.77M+299.5%
2019Dec 31, 2019$223.24M+1582.3%
2018Dec 31, 2018$13.27M–

More BioXcel Therapeutics figures

See a number that looks wrong?